Genmab

	28/5 08:44 af Parasitism	God morgen :-)
	28/5 07:13 af bibob	God morgen :-)
	28/5 05:05 af transalp	Go morgen .. :)
	27/5 20:55 af Helge Larsen/PI-redaktør	Tak Pensionist. :-)
	27/5 17:09 af GeorgeBest	ASCO: Stay alert. Fradag kl. 14 er der virtuelle præsentationer af Epcoritamab, Amivantamab, TV og Teclistamab
	27/5 16:49 af E L	Novartis' repurposed leukemia drug tops Sanofi's Aubagio in MS study weeks ahead of FDA verdict (link)
	27/5 16:37 af troldmanden	Rentschler er bare en alm CRO deal. Alle selskaber har sådan nogle deals. Det er genmab der betaler en CRO for at producere små batches antistoffer til div prækliniske og kliniske forsøg. No news
	27/5 16:06 af E L	the Ofatumumab Autoinjector trial completed -nicely on time (link)
	27/5 15:56 af Solsen	The validation on Genmabs bispecific, we have seen lately seems wake some interest in colloborations.
	27/5 15:53 af Bulder	Biotech has performed well lately, so when it comes to rebalancing, biotech will be hit.
	27/5 15:45 af E L	yes, tech and biotech clearly underperforming today -possibly also a bit of rotation/rebalancing before month-end
	27/5 15:38 af Helge Larsen/PI-redaktør	Novo, Zeal, Bava, Ambu m.fl falder tungt i dag.
	27/5 15:31 af concillado	Up, up and away!! ^^
	27/5 15:28 af concillado	Cool, thx EL :)
	27/5 15:18 af StockBull	Enten ud af kanalen og vidre op eller retracement og så blive i kanalen indtil vi når kurs 3000 Maj 2022 (link)
	27/5 15:15 af GeorgeBest	Så Genmab køber ingen fabrik i denne omgang ;-)
	27/5 15:14 af GeorgeBest	The work we will do for Genmab at our U.S. site represents a first-of-its-kind collaboration that will involve several novel projects and enable the client to decide in a flexible and agile way which projects to advance and when.”
	27/5 15:11 af GeorgeBest	Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: “We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we
	27/5 15:10 af GeorgeBest	Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: “We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we
	27/5 15:09 af GeorgeBest	LAUPHEIM, Germany and MILFORD, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the company has entered into a strategic collaboration with Genmab for the process development and manufacture of bispecific antibodies generated with Genmab’s DuoBody® technology platform. This partnership uses an innovative business model which fits well with the expansion plans f
	27/5 15:05 af GeorgeBest	Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility - GlobeNewswire 27-May-2020 15:00:10For best results when printing this announcement, please click on link below: (link) * Innovative agreement provides flexible model to address Genmab’s development and manufacturing needs as programs advance in development * Rentschler Biopharma’s U.S. site expansion progressing on tra
	27/5 15:04 af GeorgeBest	Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility
	27/5 15:04 af E L	-Daratumumab significantly derisked, with 1st line and SC approvals and new disease areas underway – much further developed pipeline and Tepezza and Ofa approved -abundance of cash
	27/5 15:03 af AaBforever	Stock...og?

	27/5 15:02 af StockBull	Ser dog ud til at ufattelig mange er gået ind i Genmab i Maj måned som har det største grønne måneds candlelight i over 10 år så det kunne indikere en måske lidt mindre retracement og exit af den gamle trendkanal fra 2018 ?
	27/5 14:57 af concillado	Compared to the "ATH 1500 scenario" 3 years ago, what would be the biggest counter argument for history not repeating itself in your opinion?
	27/5 14:52 af Sukkeralf	soon there again
	27/5 14:47 af E L	;-)
	27/5 14:47 af E L	18/5 15:13 af Parasitism WUUUHUUU
	27/5 14:42 af StockBull	Pæn støtte i 1650 som jeg ser som realistisk retracement niveau inden udgang af Juni. Ufattelig god partnerdel kan muligvis mindske retracement :-)
	27/5 14:41 af concillado	Let's have a takeover offer just in time for the summer holidays! :D
	27/5 14:40 af concillado	Positive thinking EL, I like it! :)
	27/5 14:39 af E L	1.5 to go !!
	27/5 14:39 af E L	it is only just over a week ago that we were counting down to 2000 ; Mr Market is just giving us a second chance ;-)
	27/5 14:36 af concillado	Vildt nok, hvor let det er at manipulere kursen på volatile aktier, selvom GEN egentlig ikke burde være så volatil en aktie længere, hvis man ser på trackrecord.
	27/5 14:31 af Sukkeralf	Hvis en evt partner køber sig ind i Genmab, så kan det jo være de lige har bestilt en rundbarbering af aktien først !
	27/5 14:30 af Sukkeralf	Ønske scenariet lige nu ville være LBA med dara i amyloidosis i morgen og epcoritmab data fredag samt partner aftale !
	27/5 14:28 af Sukkeralf	Faldet sker trods alt heller ikke under voldsom omsætning, så vi kan hurtigt komme den anden vej igen. Men gevinsthjemtagning må jo komme før eller siden.
	27/5 14:27 af Sukkeralf	me too
	27/5 14:26 af Solsen	Sikke en pinsefest
	27/5 14:25 af concillado	"Socks"-deal ;-)
	27/5 14:25 af Solsen	Jeg tror på weekenden :-)
	27/5 14:25 af Sukkeralf	Midten af året er vel juni-juli, men jeg synes det ville være oplagt med ekstra reklame ved ASCO eller EHA. Ikke sikkert Jan synes det :-)
	27/5 14:24 af concillado	Så har de travlt! ;-)
	27/5 14:24 af Sukkeralf	Omkring midten af året hvis ikke tidligere - det er Jans ord oversat
	27/5 14:23 af Bisseministeren	Skulle partneraftalen ligge i hus inden afslutningen af første halvår af 2020? :)
	27/5 14:23 af Sukkeralf	De lever i hvert fald ikke op til de krav Jan gerne vil have - så skulle de gå efter hele selskaber for at forbedre sin position indenfor oncologi
	27/5 14:22 af Solsen	Intet er umuligt i den brance. Men umiddelbart tror jeg den holder højde indtil partneraftalen.
	27/5 14:21 af concillado	Men jeg kommer til at tænke på for 3 år siden hvor vi ramte ATH ca. kurs 1500 og efterfølgende kun sivede nedad til ca. 800 før vi atter steg igen!
	27/5 14:21 af Solsen	Jeg tror heller ikke jeg er begejstret i den retning.